This week, Mike and Jeremy dig into the latest development out of Amylyx Pharmaceuticals, which recently announced findings of a phase 2 clinical trial of AMX0035, a drug compound shown to be safe and clinically effective at slowing down disease progression. They are joined by Dr. Neil Thakur, Chief of Mission at The ALS Association, and Dr. Jinsy Andrews, the Director of Neuromuscular Clinical Trials at Columbia University’s Irving Medical Center and a member of The ALS Association’s Board of Trustees to discuss the safety and effectiveness of AMX0035 and how to work with Amylyx and the FDA to make this drug available to people living with ALS as soon as possible.
Read more about the AMX0035 trial here: https://www.nejm.org/doi/full/10.1056/NEJMoa1916945?
Sign the petition calling on Amylyx and the FDA to expedite access to AMX0035 here: https://als.quorum.us/campaign/28538/
Learn more about The ALS Association’s work to make sure people with ALS have access to AMX0035 as quickly as possible here: https://www.als.org/stories-news/als-association-i-am-als-call-amylyx-fda-make-promising-new-drug-available-our-als
This episode was produced by Garrett Tiedemann and is brought to you by The ALS Association’s national office and the Association’s Minnesota/North Dakota/South Dakota Chapter.